New Molecular Entity
Hovilpri (pritelivir) tablets, for oral use
FDA-Approved Indication
Treatment of mucocutaneous lesions caused by herpes simplex virus (HSV) infection in immunocompromised adults that is refractory, with or without documented resistance, to acyclovir, valacyclovir, or famciclovir.
Dosage & Administration
400 mg orally on Day 1, followed by 100 mg orally once daily until HSV lesions have healed.
Dosage Forms & Strengths
Tablets: 100 mg.
Warnings & Precautions
- Drug interactions with certain acid-reducing agents
Common Adverse Reactions
Headache.
Drug Interaction
- Proton pump inhibitors
- H2-receptor antagonists
- Antacids
Clinical Studies
The approval came from PRIOH-1 Part C, a Phase 3, randomized, open-label, comparator-controlled superiority trial in 101 immunocompromised adults with mucocutaneous HSV infection refractory to acyclovir, valacyclovir, or famciclovir. Patients received Hovilpri or investigator’s choice of IV foscarnet, IV/topical cidofovir, or 5% topical imiquimod. The primary endpoint was complete lesion healing during treatment through Day 28. Hovilpri achieved a response rate of 63% versus 34% with one of the other medications (adjusted treatment difference 28.4%; P=0.0047).
Place in Therapy
Hovilpri offers a new oral treatment option, offering an alternative to IV therapies. Pritelivir inhibits the HSV helicase-primase complex and has a mechanism distinct from currently available antiviral therapies targeting viral DNA polymerase. The novel mechanism offers activity against acyclovir- and foscarnet-resistant HSV strains.
Hibsago (bepirovirsen) injection, for subcutaneous use
FDA-Approved Indication
In combination with nucleos(t)ide analog reverse transcriptase inhibitor (NrtI) therapy for treatment of chronic hepatitis B virus (HBV) infection in adult patients without cirrhosis who have been on NrtI therapy for at least 6 months and have suppressed HBV DNA, and who have HBV surface antigen (HBsAg) levels less than or equal to 3,000 IU/mL as determined by an FDA-authorized test.
Dosage & Administration
300 mg subcutaneously twice weekly during Weeks 1 and 2 followed by 300 mg once weekly during Weeks 3 through 24.
Dosage Forms & Strengths
Injection: 150 mg/mL solution in a single-dose prefilled syringe.
Contraindication(s)
- Patients with acute hepatic impairment or cirrhosis with mild, moderate, or severe hepatic impairment (Child-Pugh Class A, B, or C).
- Patients with platelet count <100 × 10⁹/L prior to treatment initiation.
Common Adverse Reactions
Injection site reactions, pyrexia, fatigue, headache.
Drug Interaction
- Anticoagulants, antiplatelets or drugs that decrease platelet count
- Drugs that impair renal function
- Peginterferon alfa-2a
Warnings & Precautions
- BBW: On-Treatment Hepatic Flares and Thrombocytopenia
- Worsening Renal Function
- Serious Inflammatory and Immune Adverse Reactions
- Serious Adverse Reaction with Improper Administration
- Post-Treatment Exacerbations of HBV Infection after Discontinuation
- Risk of HIV-1 Virologic Failure in Patients with HBV/HIV-1 Coinfection
Clinical Studies
The approval came from B-Well 1 and B-Well 2, two Phase 3, randomized, double-blind, placebo-controlled trials. Patients were randomized 2:1 to receive Hibsago or placebo for 24 weeks in addition to background NrtI therapy. At 24 weeks after eligible patients discontinued NrtI therapy, sustained HBV DNA suppression with undetectable HBsAg was achieved in 20% vs 0% in B-Well 1 and 19% vs 0% in B-Well 2 for Hibsago versus placebo, respectively.
Place in Therapy
Hibsago represents a novel treatment approach for selected adults with chronic hepatitis B whose HBV DNA is already suppressed with NrtI therapy. It is the first antisense oligonucleotide approved for chronic hepatitis B. Hibsago is administered for 24 weeks in addition to background NrtI therapy, rather than as a stand-alone treatment, and its use is limited to a defined noncirrhotic population requiring additional laboratory monitoring.
New Formulations, Combinations, and Line Extensions
Weltruza (olanzapine) extended-release suspension, for subcutaneous use
FDA-Approved Indication
Treatment of schizophrenia in adults.
Dosage & Administration
318 mg, 425 mg, or 531 mg subcutaneously once monthly, based on the corresponding oral olanzapine dose.
Dosage Forms & Strengths
Powder for extended-release injectable suspension for subcutaneous use only: 318 mg, 425 mg, and 531 mg.
Warnings & Precautions
- BBW: Increased Mortality in Elderly Patients with Dementia-Related Psychosis
- Post-Injection Delirium/Sedation Syndrome
- Neuroleptic Malignant Syndrome
- Drug Reaction with Eosinophilia and Systemic Symptoms
- Metabolic Changes
- Tardive Dyskinesia
- Orthostatic Hypotension
- Leukopenia, Neutropenia, and Agranulocytosis
- Seizures
- Potential for Cognitive and Motor Impairment
- Anticholinergic (antimuscarinic) Effects
- Hyperprolactinemia
- Laboratory Tests
Common Adverse Reactions
Weight increased, somnolence, headache, constipation, and injection site reactions (induration, pain, erythema, pruritus, swelling).
Use In Specific Populations
- Pregnancy
Drug Interaction
- Strong CYP1A2 Inducers and Inhibitors
- Centrally Acting Drugs and Alcohol
- Anticholinergic Drugs
- Antihypertensive Agents
- Levodopa and Dopamine Agonists
Clinical Studies
The approval came from the phase 3 SOLARIS trial, a multinational, randomized, double-blind, placebo-controlled study in 675 patients with an acute exacerbation of schizophrenia. Patients were randomized 1:1:1:1 to Weltruza 318 mg, 425 mg, 531 mg, or placebo for 8 weeks, followed by a 48-week safety period. At Week 8, all three doses significantly improved PANSS total scores versus placebo, with treatment differences of −9.75, −11.27, and −9.76 points, respectively. Significant improvements were also observed in CGI-S and PSP scores across all three doses.
Place in Therapy
Weltruza is the first and only once-monthly subcutaneous olanzapine LAI for adults with schizophrenia. It does not require a loading dose, oral supplementation, nor post-injection monitoring. Although post-injection monitoring is not required, Weltruza retains the class Boxed Warning for increased mortality in elderly patients with dementia-related psychosis.
New Biosimilars
New FDA-Approved Products
Other Notable Approvals
Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) solution for intramuscular injection
- To reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis.
Yulzety (rivaroxaban) oral suspension
- For the treatment or prevention of venous thromboembolic events, including DVT, PE, stroke/systemic embolism associated with nonvalvular atrial fibrillation, and VTE in eligible adult and pediatric patients.
Axycis (cisplatin) injection, for intravenous use
- [1] Advanced testicular cancer; [2] Advanced ovarian cancer; [3] Advanced bladder cancer.
Evoxac (cevimeline hydrochloride) oral solution
- For the treatment of symptoms of dry mouth in adults with Sjögren’s disease.
New First-Time Generic Approvals
First-Time Generics are the first generic forms of brand name drugs. The generic version is formulated to work in the same way as the brand-name product and provides the same clinical benefit.
New FDA-Approved Indications for Existing Drugs
The following table contains drugs that have gained FDA approval for the treatment of additional diseases or conditions.
Drug Pipeline
Denecimig
Estimated Launch Date: Mid 2027
Overview
Dencemig (Mim8) is an investigational, next-generation, subcutaneous factor VIIIa (FVIIIa)-mimetic bispecific antibody being evaluated for routine prophylaxis to prevent or reduce bleeding episodes in adult and pediatric patients with hemophilia A, with or without factor VIII inhibitors. Hemophilia A is characterized by a deficiency of factor VIII, which impairs the normal blood-clotting process. Mim8 is designed to bridge activated factor IX (FIXa) and factor X (FX), mimicking the normal activity of FVIIIa and enhancing the activation of FX to restore effective blood clotting. Unlike factor VIII replacement therapy, Mim8 provides FVIIIa-like activity without replacing the missing factor VIII protein. If approved, Mim8 would provide a subcutaneous prophylactic treatment option for patients with hemophilia A, regardless of inhibitor status.
Clinical Studies
The clinical development program for dencemig includes the pivotal Phase 3 FRONTIER2 and FRONTIER3 studies and the FRONTIER4 open-label extension study. FRONTIER2 evaluated once-weekly (QW) and once-monthly (QM) denecimig prophylaxis in adult and pediatric patients. Over 52 weeks, both regimens provided sustained bleed protection. Among patients previously receiving on-demand treatment, the estimated mean annualized bleeding rate (ABR) for treated bleeds was 0.57 with QW and 0.20 with QM denecimig, compared with 15.76 with continued on-demand treatment, representing reductions of 96.4% and 98.7%, respectively. FRONTIER3 evaluated QW and QM denecimig in children younger than 12 years with hemophilia A, with or without inhibitors. Over 52 weeks, the mean ABR was 0.42 with QW and 0.25 with QM dosing, and 81.6% and 87.5% of patients, respectively, experienced no treated bleeding episodes. The FRONTIER4 open-label extension study evaluated once-every-two-weeks (Q2W) prophylaxis and the long-term safety of QW, Q2W, and QM dosing. In an interim analysis of patients receiving Q2W denecimig, the estimated mean ABR for treated bleeding episodes was 0.4, the median ABR was 0, and 84% of patients experienced no treated bleeding episodes.
Place in Therapy
Dencemig would become the first FVIIIa mimetic to offer flexible once-weekly (QW), once-every-two-weeks (Q2W), and once-monthly (QM) dosing in a single-use, prefilled pen. It would compete most directly with Hemlibra, the only other subcutaneous FVIIIa mimetic used for routine prophylaxis in adults and pediatric patients, including newborns, with hemophilia A with or without factor VIII inhibitors. Hemlibra offers similar dosing intervals but is supplied in single-dose vials that require the patient or caregiver to draw the prescribed dose into a syringe for subcutaneous administration. Dencemig would also compete with other subcutaneous non-factor prophylactic therapies, including Alhemo, Hympavzi, and Qfitlia, as well as factor VIII replacement products.
Generic Drug Pipeline
This section describes generics that may possibly be available on the market in the next month. The estimated availability date is subject to change based on various legal factors.
The pharmacy benefit story moves fast. Keep the whole picture in view.
The Pharmacy Benefit Brief delivers perspective on cost, policy, and member protection. One email, once a month.

The view from inside the benefit
Expert insights from pharmacists and PBM operators with an inside view of where pharmacy decisions break down, what those gaps cost, and how they affect benefit performance.
See the whole pharmacy picture.
Send us your claims data and we'll show you the avoidable cost and clinical risk hiding in it.



